Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Sorbonne Universite, Universite Paris Descartes, Assistance Publique-HôPitaux De Paris (Aphp)
InventorsSelim ARACTINGI, Mathieu CATELA, Dany NASSAR, Zhe WANG
Estimating the term…
The present invention relates to methods and pharmaceutical compositions for the treatment of tissue lesions. The inventors showed that CCR2 is expressed on FMCs, especially on a subpopulation of progenitor cells, that they call “fetal myeloid progenitor cells” (FMPCs), and mediates the recruitment of these cells to maternal wound tissue. Moreover, the inventors reported that recruited FMCs/FMPCs improve maternal skin wound healing by organizing blood vessel endothelium and secreting pro-angiogenesis peptides, particularly chemokine CXCL1, to enhance angiogenesis in wound. In particular, the present invention relates to CCR2 agonists for use in the treatment of tissue lesions in a subject in need thereof.
A method of treating a tissue lesion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CCR2 agonist.
A method for screening a drug for the treatment of tissue lesions comprising the steps of i) providing a plurality of test substances ii) determining whether the test substances are CCR2 agonists and iii) positively selecting the test substances that are CCR2 agonists.
Dependencies are inferred from the claim text.